Abeona Therapeutics (ABEO) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Abeona Therapeutics is the larger company by market cap ($253.3 million vs $252.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | VCRE |
|---|---|---|
| Share price | $4.43 | $8.98 |
| Market cap | $253.33M | $252.92M |
| 1-day change | -4.73% | -1.21% |
| YTD return | -15.94% | — |
| 1-year return | -17.66% | — |
| 5-year return | -79.40% | — |
| EPS (TTM) | $-1.18 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.82M | — |
| Net income (latest FY) | $71.18M | — |
| Gross margin | 73.68% | — |
| Operating margin | -1536.91% | — |
| Net margin | 1223.08% | — |
| 52-week high | $7.65 | $17.80 |
| 52-week low | $4.00 | $7.88 |
| Distance from 52-week high | -42.09% | -49.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +326.19% | +223.83% |
| Average volume | 1.40M | 17.84K |
| Shares outstanding | 57.18M | 28.16M |
| Employees | 226 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
ABEO vs VCRE FAQ
Which is bigger, Abeona Therapeutics or Vicore Pharma AB?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $253.33M compared with $252.92M for Vicore Pharma AB (VCRE).
Are Abeona Therapeutics and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.